AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29908078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 73
Study 29908078 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 73
Study 29908435 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV)
Number of subjects: 1558
Study 29908435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1558
Study 29908521 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of respiratory viruses
Number of subjects: 774
Study 29908521 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus
Number of subjects: 774
Study 29908521 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus
Number of subjects: 774
Study 29908521 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterovirus
Number of subjects: 774
Study 29908521 — intervention group
Group type: COMPARATOR
Intervention: RSVA
Number of subjects: 774
Study 29908521 — intervention group
Group type: COMPARATOR
Intervention: RSVB
Number of subjects: 774
Study 29908521 — intervention group
Group type: COMPARATOR
Intervention: Influenza A
Number of subjects: 774
Study 29908521 — intervention group
Group type: COMPARATOR
Intervention: Influenza B
Number of subjects: 774
Study 29908521 — intervention group
Group type: COMPARATOR
Intervention: Parainfluenza virus 1
Number of subjects: 774
Study 29908521 — intervention group
Group type: COMPARATOR
Intervention: Parainfluenza virus 4
Number of subjects: 774
Study 29908521 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple virus detection
Number of subjects: 774
Study 29908967 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (with aspirin)
Number of subjects: 8582
Study 29908967 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher platelet reactivity unit (PRU) levels
Number of subjects: 8582
Study 29909069 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg DSM265
Number of subjects: 45
Study 29909069 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg DSM265
Number of subjects: 45
Study 29909069 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg DSM265
Number of subjects: 45
Study 29909069 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg DSM265
Number of subjects: 45
Study 29909101 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein apheresis
Number of subjects: 8
Study 29909109 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin-taking patients (n = 781)
Number of subjects: 1255
Study 29909549 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily plus dasabuvir 250 mg twice daily for 12 weeks (HCV patients)
Number of subjects: 790
Study 29909549 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily plus dasabuvir 250 mg twice daily for 14 days (healthy subjects)
Number of subjects: 790
Study 29909549 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily plus dasabuvir 250 mg twice daily with ribavirin 1000 or 1200 mg divided twice daily (patients with compensated cirrhosis)
Number of subjects: 790
Study 29909774 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal breath-hold during cardiovascular magnetic resonance imaging (CMR)
Number of subjects: 17
Study 29910040 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion
Number of subjects: 389
Study 29910040 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sodium bicarbonate)
Number of subjects: 389
Study 29910050 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (direct renin inhibitor) for 6 months
Number of subjects: 0
Study 29910127 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical-grade hPESC-derived midbrain dopaminergic (DA) neurons
Number of subjects: 0
Study 29910190 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose lipid kinetics measurement
Number of subjects: 52
Study 29910193 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO closure
Number of subjects: 3560
Study 29910193 — intervention group
Group type: COMPARATOR
Intervention: Antithrombotic therapy (antiplatelet therapy or anticoagulation)
Number of subjects: 3560
Study 29910764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological RAS
Number of subjects: 32
Study 29910764 — intervention group
Group type: COMPARATOR
Intervention: Artificial RAS
Number of subjects: 32
Study 29911480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL) using the Shockwave Medical Peripheral IVL System
Number of subjects: 20
Study 29911997 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive infusion of the broadly neutralizing antibody VRC01 during analytical treatment interruption (ATI)
Number of subjects: 0
Study 29912343 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.7 GBq radioactive iodine (RAI) therapy
Number of subjects: 40
Study 29912813 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvesicles and micro-RNAs measurement
Number of subjects: 24
Study 29912924 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 22
Study 29912954 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-assisted training for community health workers
Number of subjects: 572
Study 29912954 — intervention group
Group type: COMPARATOR
Intervention: Paper-based training for community health workers (Control)
Number of subjects: 572
Study 29913339 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 57
Study 29913339 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 57
Study 29913339 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (≥0.15 µg/kg/min)
Number of subjects: 57
Study 29914446 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention to enhance knowledge of, access to, and use of insurance and available services to reduce healthcare disparities.
Number of subjects: 0
Study 29914509 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported fatigue severity (EORTC QLQ-C30)
Number of subjects: 312
Study 29914509 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PRO) assessments using EORTC QLQ-C30, EORTC QLQ-MY20, EORTC QLQ-INFO25
Number of subjects: 312
Study 29914509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression analyses
Number of subjects: 312
Study 29914528 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 9
Study 29914544 — intervention group
Group type: EXPERIMENTAL
Intervention: S1226 (8% CO2)
Number of subjects: 0
Study 29914544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29914560 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy with CT scans
Number of subjects: 993
Study 29914560 — intervention group
Group type: COMPARATOR
Intervention: Absence of history of severe hemorrhage, dual antiplatelet therapy, headache or vomiting, and abnormal Glasgow coma scale score
Number of subjects: 993
Study 29914796 — intervention group
Group type: EXPERIMENTAL
Intervention: Convection-enhanced delivery of a radioimmunotherapy agent targeting B7-H3 antigen, single infusion of 9.25 to 148 MBq at a concentration of about 37 MBq/mL.
Number of subjects: 28
Study 29914867 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR) in symptomatic patients
Number of subjects: 99
Study 29914867 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline midwall late gadolinium enhancement (LGE) in asymptomatic patients
Number of subjects: 99
Study 29914867 — intervention group
Group type: COMPARATOR
Intervention: Natural progression in asymptomatic patients
Number of subjects: 99
Study 29914948 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin treatment
Number of subjects: 21
Study 29914960 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (RIF)
Number of subjects: 0
Study 29914960 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (PZA)
Number of subjects: 0
Study 29914960 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 0
Study 29914960 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol (EMB)
Number of subjects: 0
Study 29914960 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples collected predose and at 1, 2, 4, and 8 hours postdose.
Number of subjects: 0
Study 29914960 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian estimation
Number of subjects: 0
Study 29914960 — intervention group
Group type: EXPERIMENTAL
Intervention: Bland-Altman plots
Number of subjects: 0
Study 29915522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 157
Study 29915786 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of tissue cultures and 16S rRNA gene polymerase chain reaction
Number of subjects: 0
Study 29915786 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29915941 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced neutrophil CD88
Number of subjects: 148
Study 29915941 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced monocyte HLA-DR
Number of subjects: 148
Study 29915941 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated proportions of regulatory T cells (Tregs)
Number of subjects: 148
Study 29916117 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) alone
Number of subjects: 26
Study 29916117 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) concomitantly with erlotinib
Number of subjects: 26
Study 29916861 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous noninvasive blood pressure monitoring
Number of subjects: 316
Study 29916861 — intervention group
Group type: COMPARATOR
Intervention: Intermittent blood pressure monitoring
Number of subjects: 316
Study 29917066 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude of low-frequency fluctuation (ALFF) in PD patients
Number of subjects: 49
Study 29917066 — intervention group
Group type: COMPARATOR
Intervention: Amplitude of low-frequency fluctuation (ALFF) in healthy controls
Number of subjects: 49
Study 29917066 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional homogeneity (ReHo) in PD patients
Number of subjects: 49
Study 29917066 — intervention group
Group type: COMPARATOR
Intervention: Regional homogeneity (ReHo) in healthy controls
Number of subjects: 49
Study 29917147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) delivered house-to-house or at a central point, with or without compensation
Number of subjects: 163
Study 29917147 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about the rationale for MDA, asymptomatic infections, and transmission
Number of subjects: 163
Study 29917147 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA delivered house-to-house by volunteers at the end of the dry season
Number of subjects: 163
Study 29917147 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA targeted at individual villages or village clusters
Number of subjects: 163
Study 29920516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime light alcohol drinkers (1-3 drinks per week)
Number of subjects: 99654
Study 29920516 — intervention group
Group type: COMPARATOR
Intervention: Lifetime never or infrequent drinkers (<1 drink/week)
Number of subjects: 99654
Study 29920516 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinkers (2-<3 drinks/day)
Number of subjects: 99654
Study 29920516 — intervention group
Group type: EXPERIMENTAL
Intervention: Very heavy drinkers (3+ drinks/day)
Number of subjects: 99654
Study 29920582 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GOL) 200 mg at week 0, 100 mg at week 2, then 50 mg (<80 kg) or 100 mg (≥80 kg) every 4 weeks thereafter.
Number of subjects: 91
Study 29920582 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GOL) with short-term mucosal healing (STMH) at week 14.
Number of subjects: 91
Study 29920582 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GOL) after week 14 with STMH.
Number of subjects: 91
Study 29920582 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort outcomes.
Number of subjects: 91
Study 29920584 — intervention group
Group type: EXPERIMENTAL
Intervention: Southern participants
Number of subjects: 1227
Study 29920584 — intervention group
Group type: COMPARATOR
Intervention: Non-Southern participants
Number of subjects: 1227
Study 29920885 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 29
Study 29920885 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 29
Study 29920885 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 29
Study 29920885 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 29
Study 29920885 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 29
Study 29921512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg per day for 4 weeks in repeated 6-week cycles until disease progression or prohibitive toxicity
Number of subjects: 30
Study 29921523 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time biofeedback (RTBF) high-loading condition (5% vGRF increase)
Number of subjects: 30
Study 29921523 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time biofeedback (RTBF) low-loading condition (5% vGRF decrease)
Number of subjects: 30
Study 29921523 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time biofeedback (RTBF) symmetrical loading condition
Number of subjects: 30
Study 29921523 — intervention group
Group type: COMPARATOR
Intervention: Control (no RTBF)
Number of subjects: 30
Study 29921557 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0
Study 29921557 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study 29921557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both surgical approaches
Number of subjects: 0
Study 29921622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory patch ECG recorder (Zio XT monitor) fitted in the ED, continuously records a single-lead ECG for up to 14 days.
Number of subjects: 86
Study 29921622 — intervention group
Group type: COMPARATOR
Intervention: Historical comparator group (no intervention mentioned).
Number of subjects: 86
Study 29921622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory patch ECG recorder (Zio XT monitor).
Number of subjects: 86
Study 29921685 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined optimisation of general anaesthesia involving goal-directed haemodynamic therapy (GDHT), lung-protective ventilation (LPV), and electroencephalographic depth of anaesthesia monitoring (DAM)
Number of subjects: 27
Study 29921685 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 27
Study 29921685 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined optimisation of general anaesthesia
Number of subjects: 27
Study 29921736 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour urine phosphorus measurement
Number of subjects: 8
Study 29921736 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 24-hour urine phosphorus measurement
Number of subjects: 8
Study 29922050 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent asthma diagnosis
Number of subjects: 19894
Study 29922050 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 19894
Study 29922050 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 19894
Study 29922096 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate/dienogest (EV/DNG)
Number of subjects: 954
Study 29922187 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and Communication Technologies intervention
Number of subjects: 428
Study 29922574 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric biomarkers
Number of subjects: 0
Study 29922574 — intervention group
Group type: EXPERIMENTAL
Intervention: FBA
Number of subjects: 0
Study 29922574 — intervention group
Group type: COMPARATOR
Intervention: Clinical scores
Number of subjects: 0
Study 29922676 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 112
Study 29922676 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine
Number of subjects: 112
Study 29923063 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic scalp cooling (PSC) with ELASTO-GEL hypothermia caps during adjuvant docetaxel treatment
Number of subjects: 492
Study 29923063 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant docetaxel (cumulative dose ≥ 400 mg/m²)
Number of subjects: 492
Study 29923063 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only endocrine therapy
Number of subjects: 492
Study 29923073 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) treatment
Number of subjects: 90
Study 29923073 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 90
Study 29923073 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP treatment
Number of subjects: 90
Study 29923092 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate
Number of subjects: 19
Study 29923092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 29923459 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented DCB lesions
Number of subjects: 224
Study 29923897 — intervention group
Group type: EXPERIMENTAL
Intervention: VCF group
Number of subjects: 39
Study 29923897 — intervention group
Group type: COMPARATOR
Intervention: Older adult group (NE)
Number of subjects: 39
Study 29923931 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic lactate (sodium lactate, 1,000 mmol/L; concentration, 30 µmol/kg/min) administered via three-hour IV infusion 39 hours from injury.
Number of subjects: 23
Study 29923931 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 23
Study 29923998 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 620
Study 29923998 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 620
Study 29924294 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat labeled yogurt (10% fat)
Number of subjects: 26
Study 29924294 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat labeled yogurt (0.1% fat)
Number of subjects: 26
Study 29924298 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Healthy Lifestyle Index (HLI) variables and metabolic signatures
Number of subjects: 294
Study 29924298 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomic profile
Number of subjects: 294
Study 29924298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle component's PLS score
Number of subjects: 294
Study 29924298 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolites sphingomyelin (SM) (OH) C14:1, C16:1, C22:2
Number of subjects: 294
Study 29924298 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate, hexoses, diacyl-phosphatidylcholine PC aaC32:1
Number of subjects: 294
Study 29924320 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum retinol
Number of subjects: 542
Study 29924320 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb)
Number of subjects: 542
Study 29924320 — intervention group
Group type: EXPERIMENTAL
Intervention: Height-for-age z score
Number of subjects: 542
Study 29924320 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-for-age z score
Number of subjects: 542
Study 29924320 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble transferrin receptor
Number of subjects: 542
Study 29924320 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 542
Study 29925332 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing medical education (CME) meeting, a four-hour educational meeting performed by GPs and specialists in palliative care.
Number of subjects: 120
Study 29925332 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic decision support (EDS), integrated into existing electronic records.
Number of subjects: 120
Study 29925332 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention (CME and EDS)
Number of subjects: 120
Study 29925332 — intervention group
Group type: EXPERIMENTAL
Intervention: CME meetings
Number of subjects: 120
Study 29925332 — intervention group
Group type: EXPERIMENTAL
Intervention: EDS
Number of subjects: 120
Study 29925376 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics (hydrochlorothiazide and chlorthalidone)
Number of subjects: 150
Study 29925397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-SAR imaging with nitinol guidewire (150 cm × 0.035" Terumo Glidewire)
Number of subjects: 7
Study 29925397 — intervention group
Group type: COMPARATOR
Intervention: Standard catheterization without guidewire
Number of subjects: 7
Study 29925397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-SAR imaging with nitinol guidewire
Number of subjects: 7
Study 29925433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomitapide
Number of subjects: 29
Study 29925433 — intervention group
Group type: COMPARATOR
Intervention: Mipomersen
Number of subjects: 29
Study 29925433 — intervention group
Group type: COMPARATOR
Intervention: Evolocumab
Number of subjects: 29
Study 29925491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app and accelerometer intervention (2 intervention groups: Regular and Plus)
Number of subjects: 203
Study 29925491 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss group (n=19)
Number of subjects: 203
Study 29925491 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Prevention group (n=138)
Number of subjects: 203
Study 29925491 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Promotion group (n=46)
Number of subjects: 203
Study 29925491 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous intensity activity level among the 3 groups
Number of subjects: 203
Study 29925497 — intervention group
Group type: EXPERIMENTAL
Intervention: CCAT (computerized cognitive addiction therapy) for 4 weeks plus regular detoxification treatment
Number of subjects: 40
Study 29925497 — intervention group
Group type: COMPARATOR
Intervention: Regular detoxification treatment as usual
Number of subjects: 40
Study 29925496 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit app intervention
Number of subjects: 39